minocycline has been researched along with Pneumonia--Pneumococcal* in 3 studies
3 other study(ies) available for minocycline and Pneumonia--Pneumococcal
| Article | Year |
|---|---|
Activity of tigecycline against Streptococcus pneumoniae, an important causative pathogen of community-acquired pneumonia (CAP).
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Humans; Microbial Sensitivity Tests; Minocycline; Pneumonia, Pneumococcal; Streptococcus pneumoniae; Switzerland; Tigecycline | 2010 |
Efficacy of a novel tetracycline derivative, glycylcycline, against penicillin-resistant Streptococcus pneumoniae in a mouse model of pneumonia.
The MIC90 of glycylcycline (< or =0.06 mg/L) against 55 strains of Streptococcus pneumoniae was 100-fold lower than that of minocycline or tetracycline. In a mouse model of penicillin-resistant S. pneumoniae (PRSP) pneumonia, glycylcycline (10 mg/kg) decreased bacterial counts in the lungs from 10(6) cfu to <10(2) cfu, whereas no apparent reduction of bacterial numbers was observed with minocycline or penicillin G. Pharmacokinetic studies showed that the half-life and area under the curve of glycylcycline were superior to those of minocycline and penicillin G in the lungs. These results show a preferential distribution of glycylcycline in the lungs and potent in vivo bactericidal activity in PRSP pneumonia. Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Female; Lung; Mice; Mice, Inbred CBA; Microbial Sensitivity Tests; Minocycline; Penicillin G; Penicillins; Pneumonia, Pneumococcal; Streptococcus pneumoniae; Tetracycline | 2000 |
Minocycline treatment failure in pneumonia caused by minocycline-sensitive Streptococcus pneumoniae.
A previously healthy 23-year-old white woman had fulminant pneumococcal pneumonia complicated by empyema and bilateral pneumothoraces. Despite early treatment with the recommended doses of minocycline, the disease progressed. The S pneumoniae isolate was resistant to a 30microgram tetracycline disk and showed an MIC of 3.13microgram/ml for minocycline and 12.5 microgram/ml for tetracycline; these levels are considered by the manufacturer to indicate sensitivity to minocycline and intermediate sensitivity to tetracycline. The tetracyclines, including minocycline, should not be used to treat bacterial pneumonia since resistant strains of pneumococci are not uncommon and inffective treatment can lead to rapid progression of the infection. This case suggests that the levels of minocycline considered to indicate sensitivity in vitro be reassessed. Topics: Adult; Drug Resistance, Microbial; Female; Humans; Microbial Sensitivity Tests; Minocycline; Pneumonia, Pneumococcal; Streptococcus pneumoniae; Tetracyclines | 1977 |